Previous 10 | Next 10 |
CAMBRIDGE, Mass., Dec. 01, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), today announced preliminary results from the ongoing Phase 1 ATTCK-17-01 study, testing ACTR087 in combination with SEA-BCMA in patients with relapsed/refractory multiple myeloma (r/r MM) at the Ameri...
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), today announced that the Company will present preclinical data on a new proprietary technology platform called B olt- O n Chi meric R eceptor, or BOXR, designed to improve the effectiveness of T ce...
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal Antibody-Coupled T-cell Receptor (ACTR) technology platform, today annou...
CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal Antibody-Coupled T cell Receptor (ACTR) technology platform, today annou...
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Waste Management, Inc. (NYSE:WM), Cubic Corporation (NYSE:CUB), Unum Ther...
CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal Antibody-Coupled T cell Receptor (ACTR) technology platform, will prese...
Unum Therapeutics Inc. (UMRX) Q2 2018 Results Earnings Conference Call August 13, 2018 05:00 PM ET Executives Mary Conway - Investor Relations Chuck Wilson - Chief Executive Officer Michael Vasconcelles - Chief Medical Officer Christiana Stamoulis - President and Chief Financia...
Unum Therapeutics (NASDAQ: UMRX ): Q2 EPS of -$0.31 beats by $0.04 . More news on: Unum Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
– IND for First Solid Tumor Program, ACTR T cells in Combination with Trastuzumab in Patients with HER2+ Advanced Cancers Now Active; Expect to Initiate Phase I Trial by End of 2018 – CAMBRIDGE, Mass., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMR...
– First Solid Tumor Product Candidate Based on Unum’s universal ACTR Technology – – Phase 1 Study Expected to Initiate by the End of 2018 – CAMBRIDGE, Mass., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, wil...
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into ...
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead progra...